Overview
Epitalon (also spelled Epithalon or Epithalone) is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly (AEDG). It was developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, based on the amino acid composition of epithalamin — a polypeptide extract of the bovine pineal gland that showed geroprotective effects in animal models.
The central claim: Epitalon activates telomerase — the enzyme that maintains telomere length — in human somatic cells, potentially extending replicative lifespan beyond the Hayflick limit. In a 2003 study, Khavinson reported that Epitalon-treated human fetal fibroblasts continued dividing past the 44th passage, while untreated controls stopped at the 34th passage. If reproducible, this would be a significant finding for aging research.
The critical limitation: Until 2025, virtually all published Epitalon research came from Khavinson's institute. A 2025 study from Brunel University (London) provided the first independent confirmation of telomere-lengthening effects in cell culture. A 2025 review in the International Journal of Molecular Sciences noted that despite 25 years of study, the compound's precise mechanism of action remains unclear. The evidence is best characterized as hypothesis-generating rather than conclusive.
Dosage & Reconstitution
- Vial strength
- 10 mg
- BAC water added
- 2 mL
- Final concentration
- 5 mg/mL
| Weeks | Dosage | Syringe units (U-100) |
|---|---|---|
| Weeks 1–3 (days 1–20) | 5 mg | 100 units1 mL |
- Vial strength
- 50 mg
- BAC water added
- 5 mL
- Final concentration
- 10 mg/mL
| Weeks | Dosage | Syringe units (U-100) |
|---|---|---|
| Weeks 1–3 (days 1–20) | 5 mg | 50 units0.5 mL |
FrequencyOnce daily for 20 consecutive days, subcutaneous, then four to six months off before the course is repeated.
Note
For review — not established human dosing. The long-term human work usually cited for Epitalon studied Epithalamin, a pineal extract, not the synthetic tetrapeptide sold under this name. The course in the chart follows a circulated research protocol. The concentration strip above the chart is calculated from the vial and water volume and is correct.
Unverified — no cited study of the synthetic tetrapeptide establishes this course.
Epitalon is given as a short course rather than a titration, which is why there is a single row: the protocol runs one amount for 20 consecutive days and then stops for four to six months, so a reader looking for weeks 4 onward should find nothing there. The evidence problem is a substitution — the multi-year Russian longevity work cited for Epitalon used Epithalamin, a pineal peptide extract, and the synthetic tetrapeptide Ala-Glu-Asp-Gly is not the same substance, so the course is flagged for review. The 10 mg vial made up with 2 mL comes to 5 mg/mL, which puts the 5 mg daily amount at 100 units — twice what a 50-unit syringe holds, so it cannot be drawn in one fill at that concentration, and it is marked on the chart rather than resolved by splitting it into two injections, because no source describes it that way. The 50 mg vial made up with 5 mL comes to 10 mg/mL, where the same amount is 50 units, exactly one full syringe with nothing to spare.
Measurement note. At this strength and water volume one or more of the amounts above is larger than the 0.5 mL a 50-unit U-100 syringe holds, so it would be drawn with a 100-unit syringe rather than in a single 50-unit fill.
What this evidence establishes. No reliable human dosing exists for synthetic Epitalon (the tetrapeptide Ala-Glu-Asp-Gly). The long-term human work most often cited for it studied Epithalamin, a pineal peptide extract, not the synthetic tetrapeptide — they are different substances and the results do not transfer. That work was also published almost entirely in Russian-language journals without independent replication. The table below is reconstitution arithmetic only.
For educational and laboratory research purposes only. It does not provide medical advice, dosing recommendations, or instructions for human or veterinary use. Syringe units assume a U-100 syringe, on which 1 mL is 100 units and a 50-unit syringe holds 0.5 mL.
Mechanism of Action
Telomerase Activation
Proposed to upregulate hTERT (the catalytic subunit of telomerase), increasing telomerase activity and extending telomere length in somatic cells
Melatonin Stimulation
Stimulates melatonin production from the pineal gland by upregulating biosynthesis enzymes (AANAT, HIOMT). May restore circadian rhythm amplitude in aging
Epigenetic Regulation
Binds to methylated cytosine in DNA and linker histone H1, potentially influencing chromatin structure and gene expression patterns
Antioxidant Effects
Reduces oxidative stress markers and stimulates antioxidant enzyme defenses. A 2025 study showed enhanced wound healing in diabetic retinopathy cell models.
Neuroprotection
Increases BDNF expression and modulates circadian gene expression. Combined with stem cell therapies in a 2024 case report showing improved cognition.
Anti-Tumor (Paradoxical)
Despite activating telomerase (typically associated with cancer), animal studies report reduced spontaneous tumor incidence — a counterintuitive finding requiring independent verification
Mechanism uncertainty: A 2025 comprehensive review (Araj et al., IJMS) stated explicitly that despite 25 years of research, "the mechanism of action remains unclear." The interaction with DNA, histones, and telomerase promoter sequences is proposed but not fully characterized.
Research Timeline
Contraindications & Safety Data
Formal toxicology data for Epitalon is limited. Russian clinical use over 30+ years has not produced published safety signals, but this data is not structured to Western pharmacovigilance standards.
| Condition / Factor | Risk Level | Rationale |
|---|---|---|
| Active cancer or malignancy | HIGH (PARADOXICAL) | Telomerase activation is the mechanism that makes cancer cells immortal. Although animal studies report anti-tumor effects, activating telomerase alongside an existing malignancy is theoretically counterproductive. This paradox is unresolved. |
| Cancer history | MODERATE | The telomerase paradox makes any cancer history a significant concern. Independent safety data in cancer survivors does not exist. |
| Pregnancy / breastfeeding | HIGH | No reproductive toxicology data. Epigenetic effects on gene expression make pregnancy exposure unpredictable. |
| Autoimmune conditions | MODERATE | Immune-modulating properties (IL-2 mRNA alteration, thymocyte activation) may unpredictably affect autoimmune disease |
| Single-source evidence | EVIDENCE CAVEAT | 25 years of research from essentially one laboratory. Independent Western replication began in 2025. The evidence base should be treated as preliminary. |
| General safety profile | LOW (limited data) | No significant adverse events reported in Russian clinical use. However, pharmacovigilance standards differ from FDA requirements and published safety data is sparse. |
Regulatory Status
Russia: Epitalon and epithalamin are approved for clinical use, particularly for age-related conditions and retinal degeneration. Over 30 years of clinical application.
FDA: Not approved. Not specifically classified under Category 2, but is not an approved drug. Available only through research chemical channels in the U.S.
The independence problem: This is the fundamental challenge with Epitalon. The research is extensive (25+ years, cell culture, animal models, primate data, case reports) but almost entirely from one laboratory. The 2025 Brunel University study is the first meaningful independent confirmation. Until more Western laboratories replicate the core findings, the evidence base carries a significant single-source limitation.
References (APA 7th Edition)
Epitalon Research Readiness Quiz
Evaluate your understanding of Epitalon's evidence base, the single-source limitation, and the telomerase paradox.